Canaccord lowered the firm’s price target on Grail (GRAL) to $80 from $105 and keeps a Buy rating on the shares. The firm said although they are disappointed with GRAIL’s NHS-Galleri top-line results and recognize the path forward may be less certain, we think the after-hours selloff (nearly 50%) is an overreaction. Canaccord remains confident in NHS Galleri results despite missing primary endpoint.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRAL:
- Closing Bell Movers: Akamai slides 8% on soft guidance
- GRAIL Reports Strong 2025 Growth and Galleri Trial Update
- Grail reports results of Galleri cancer detection test trial
- Grail reports Q4 EPS ($2.44), consensus ($2.66)
- Balancing Market Leadership and Regulatory Risk: Justifying a Hold Rating After a 450% Rally